EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma

Lirui Dai, Yongjie Han, Zhuo Yang, Yuling Zeng, Wulong Liang, Zimin Shi, Yiran Tao, Xianyin Liang, Wanqing Liu, Shaolong Zhou, Zhe Xing, Weihua Hu und 1 weitere

Journal of Cellular and Molecular Medicine · 2023

DOI: 10.1111/jcmm.17807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Lirui Dai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suppressor of cytokine signalling ( SOCS ) 1/2/3/4 are involved in the occurrence and progression of multiple malignancies; however, their prognostic and developmental value in patients with glioblastoma (GBM) remains unclear. The present study used TCGA, ONCOMINE, SangerBox3.0, UALCAN, TIMER2.0, GENEMANIA, TISDB, The Human Protein Atlas (HPA) and other databases to analyse the expression profile, clinical value and prognosis of SOCS1/2/3/4 in GBM, and to explore the potential development mechanism of action of SOCS1/2/3/4 in GBM. The majority of analyses showed that SOCS1/2/3/4 transcription and translation levels in GBM tissues were significantly higher than those in normal tissues. qRT‐PCR, western blotting (WB) and immunohistochemical staining were used to verify that SOCS3 was expressed at higher mRNA and protein levels in GBM than in normal tissues or cells. High SOCS1/2/3/4 mRNA expression was associated with poor prognosis in patients with GBM, especially SOCS3 . SOCS1/2/3/4 were highly contraindicated, which had few mutations, and were not associated with clinical prognosis. Furthermore, SOCS1/2/3/4 were associated with the infiltration of specific immune cell types. In addition, SOCS3 may affect the prognosis of patients with GBM through JAK/STAT signalling pathway. Analysis of the GBM‐specific protein interaction (PPI) network showed that SOCS1/2/3/4 were involved in multiple potential carcinogenic mechanisms of GBM. In addition, colony formation, Transwell, wound healing and western blotting assays revealed that inhibition of SOCS3 decreased the proliferation, migration and invasion of GBM cells. In conclusion, the present study elucidated the expression profile and prognostic value of SOCS1/2/3/4 in GBM, which may provide potential prognostic biomarkers and therapeutic targets for GBM, especially SOCS3 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHumansSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling 3 ProteinPrognosisSuppressor of Cytokine Signaling ProteinsRNA, MessengerBiomarkers

Stichwörter der Autor:innen

JAK/STAT3SOCS1/2/3/4biomarkersgene expression profilingglioblastomaimmune infiltration

Substanzen

Suppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsRNA, MessengerBiomarkersSOCS1 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
  • Institute of Neuroscience, Zhengzhou University, Zhengzhou, China.
  • Henan International Joint Laboratory of Glioma Metabolism and Microenvironment Research, Zhengzhou, China.
  • Department of Blood Transfusion, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Xinjun Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dai, L., Han, Y., Yang, Z., Zeng, Y., Liang, W., Shi, Z., Tao, Y., Liang, X., Liu, W., Zhou, S., Xing, Z., Hu, W., & Wang, X. (2023). Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17807

Vancouver

Dai L, Han Y, Yang Z, Zeng Y, Liang W, Shi Z, et al. Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17807

BibTeX
@article{Dai2023,
  author = {Dai, Lirui and Han, Yongjie and Yang, Zhuo and Zeng, Yuling and Liang, Wulong and Shi, Zimin and Tao, Yiran and Liang, Xianyin and Liu, Wanqing and Zhou, Shaolong and Xing, Zhe and Hu, Weihua and Wang, Xinjun},
  title = {Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  doi = {10.1111/jcmm.17807}
}
Kostenlos starten →